BACKGROUND: Recurrent head and neck squamous cell carcinoma (HNSCC) remains a difficult cancer to treat. Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG-479 (monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R]). METHODS: The clinical information was collected by a retrospective medical record review under an Institutional Review Board-approved protocol. From 4 tumors and 2 normal mucosal epithelia, global gene expression, and IGF-1R and dihydrofolate reductase (DHFR) protein levels were determined. RESULTS: Effective target inhibition in the tumor was confirmed by the decreased protein levels of total and phospho-IGF-1R after treatment with AMG-479. Decreased level of DHFR and conversion of a gene expression profile associated with cetuximab-resistance to cetuximab-sensitivity were also observed. CONCLUSION: This suggests that the combination of AMG-479 and MTX or cetuximab may be a promising therapeutic approach in refractory HNSCC.
BACKGROUND: Recurrent head and neck squamous cell carcinoma (HNSCC) remains a difficult cancer to treat. Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG-479 (monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R]). METHODS: The clinical information was collected by a retrospective medical record review under an Institutional Review Board-approved protocol. From 4 tumors and 2 normal mucosal epithelia, global gene expression, and IGF-1R and dihydrofolate reductase (DHFR) protein levels were determined. RESULTS: Effective target inhibition in the tumor was confirmed by the decreased protein levels of total and phospho-IGF-1R after treatment with AMG-479. Decreased level of DHFR and conversion of a gene expression profile associated with cetuximab-resistance to cetuximab-sensitivity were also observed. CONCLUSION: This suggests that the combination of AMG-479 and MTX or cetuximab may be a promising therapeutic approach in refractory HNSCC.
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Andrew P Gilmore; Anthony J Valentijn; Pengbo Wang; Ann M Ranger; Nigel Bundred; Michael J O'Hare; Alan Wakeling; Stanley J Korsmeyer; Charles H Streuli Journal: J Biol Chem Date: 2002-05-13 Impact factor: 5.157
Authors: B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson Journal: Science Date: 2004-04-29 Impact factor: 47.728
Authors: Pedro J Beltran; Petia Mitchell; Young-A Chung; Elaina Cajulis; John Lu; Brian Belmontes; Joanne Ho; Mei Mei Tsai; Min Zhu; Steven Vonderfecht; Renato Baserga; Richard Kendall; Robert Radinsky; Frank J Calzone Journal: Mol Cancer Ther Date: 2009-04-14 Impact factor: 6.261
Authors: Christopher J Barnes; Kazufumi Ohshiro; Suresh K Rayala; Adel K El-Naggar; Rakesh Kumar Journal: Clin Cancer Res Date: 2007-07-15 Impact factor: 12.531
Authors: Brandon Leonard; Toni M Brand; Rachel A O'Keefe; Eliot D Lee; Yan Zeng; Jacquelyn D Kemmer; Hua Li; Jennifer R Grandis; Neil E Bhola Journal: Cancer Res Date: 2018-05-23 Impact factor: 12.701
Authors: Hilary S Parker; Jeffrey T Leek; Alexander V Favorov; Michael Considine; Xiaoxin Xia; Sameer Chavan; Christine H Chung; Elana J Fertig Journal: Bioinformatics Date: 2014-06-06 Impact factor: 6.937
Authors: Josep Tabernero; Sant P Chawla; Hedy Kindler; Karen Reckamp; E Gabriela Chiorean; Nilofer S Azad; A Craig Lockhart; Cheng-Pang Hsu; Nigel F Baker; Francesco Galimi; Pedro Beltran; José Baselga Journal: Target Oncol Date: 2014-05-11 Impact factor: 4.493
Authors: Amanda Psyrri; Ju-Whei Lee; Eirini Pectasides; Maria Vassilakopoulou; Efstratios K Kosmidis; Barbara A Burtness; David L Rimm; Harold J Wanebo; Arlene A Forastiere Journal: Clin Cancer Res Date: 2014-04-03 Impact factor: 12.531
Authors: Peter M Anderson; Stefan S Bielack; Richard G Gorlick; Keith Skubitz; Najat C Daw; Cynthia E Herzog; Odd R Monge; Alvaro Lassaletta; Erica Boldrini; Zsuzanna Pápai; Joseph Rubino; Kumudu Pathiraja; Darcy A Hille; Mark Ayers; Siu-Long Yao; Michael Nebozhyn; Brian Lu; David Mauro Journal: Pediatr Blood Cancer Date: 2016-06-30 Impact factor: 3.167